Press Releases

Date Headline
7/11/2024
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
 Summary
VANCOUVER, British Columbia , July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
6/17/2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
 Summary
VANCOUVER, British Columbia , June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the  Continue Reading
6/10/2024
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
 Summary
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License  Continue Reading
5/28/2024
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia , May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
5/2/2024
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
 Summary
Reported $420.5 million in cash resources as of March 31, 2024 , which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics license application (BLA) filing with the U.S.  Continue Reading
4/30/2024
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia , April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
4/11/2024
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
 Summary
VANCOUVER, British Columbia , April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
4/8/2024
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
 Summary
VANCOUVER, British Columbia , April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced five  Continue Reading
3/28/2024
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
 Summary
VANCOUVER, British Columbia , March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the  Continue Reading
3/27/2024
Zymeworks Announces Participation in Upcoming Investor Conferences
 Summary
VANCOUVER, British Columbia , March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that  Continue Reading
Displaying 1 - 10 of 18